Overview

A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Young and elderly, male and female subjects are each given 2 different doses of mirabegron for 7 days each. Levels of mirabegron in the blood are assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Mirabegron